Syntonix Pharmaceuticals Harvard Case Solution & Analysis

The company had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then used that technology to develop new therapies to treat chronic diseases. The Transceptor® technology utilized a unique biological pathway to allow efficient delivery of SynFusion™ drug therapies. Several firms licensed the technologies in combined development deals to address Hemophilia B several different conditions, autoimmune disorders, and infertility infertility, as well as for use in enhanced peptide inhalation.

The firm had used up Rounds An and B and Angel cash of venture capital funding and was looking for an added $80 - $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to obtain a 'C' Round of capital. One member of the proposed syndicate, Biogen Idec, signaled interest in purchasing Syntonix. The creators needed to make a decision about the offer.

Syntonix Pharmaceuticals case study solution

PUBLICATION DATE: January 25, 2009 PRODUCT #: NA0034-HCB-ENG

This is just an excerpt. This case is about FINANCE & ACCOUNTING

Syntonix Pharmaceuticals Case Solution Other Similar Case Solutions like

Syntonix Pharmaceuticals

Share This